Brilinta
Brilinta

3.11
For patients managing blood pressure and heart conditions, this generic medicine prevents blood clots. Inhibits platelet aggregation in the bloodstream to lower the risk of cardiovascular events occurring.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Ticagrelor
Reference Brand
Ticagrelor
Product Origin
Generic Alternative
Reference Manufacturer
AstraZeneca
Product Form
Tablet
Regulatory Classification
Prescription Only Medicine
Primary Category
Anticoagulants
Product Category
P2Y12 Platelet Inhibitor
Pharmacological Class
Antiplatelet Agent
Manufacturer Description
Utilized to manage platelet aggregation to alleviate risk of vascular occlusion and support coronary circulation.
Mechanism of Action
Reversibly binds to P2Y12 adenosine diphosphate receptors on platelets, preventing physical activation and clotting cascade.
Route of Administration
Oral
Onset Time
30–60 minutes
Duration
12 hours
Contraindications
Active pathological bleeding, History of intracranial hemorrhage, Severe hepatic impairment
Severe Adverse Events
Severe internal hemorrhage — requires immediate medical attention
Common Side Effects
Shortness of breath, Nosebleeds
Uncommon Side Effects
Easy bruising, Headache, Dizziness
Drug Interactions
Aspirin, Ketoconazole, Simvastatin
Pregnancy Safety Warnings
TGA Category C: Use if potential therapeutic benefit justifies fetal risks. Breastfeeding: Consult a doctor.
Age Restrictions
Approved for adults.
Storage Guidelines
Store below 25°C.
Related Products
Information related to Brilinta is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
how to access Overactive Bladder Treatment - Buy Mirabegron AU